Abstract
The authors Analyzed the immediate and remote results of treatment of patients with prostate cancer treated by the method - a robotic radiotherapy. Immediate results of treatment were estimated on the level of total PSA, prostate volume, residual urine, change according to the international scale IPSS. The dynamics of the above indicators showed regression of the primary lesion, and the absence of pronounced radiation reactions affect the quality of life of patients. We analyzed the results of overall, relapse-free survival and oncospecific. Three-year disease-free survival in patients receiving radiation therapy is of 88.8%. Overall survival, as well as oncospecific survival rate is 100%. Also presents first experience of using stereotactic radiotherapy in patients of renal cell carcinoma. Treatment received two (one patient carried out the irradiation of both kidneys). In one patient, complete tumor resorption of the right kidney and a decrease in the size and reduction of contrast enhancement of the tumor of the left kidney. Renal function did not deteriorate. The second patient decreased the size of the tumor, but preserved the contrast enhancement in the vascular phase. The only function of the kidney has not deteriorated.
Highlights
remote results of treatment of patients with prostate cancer treated by the method - a robotic radiotherapy
Immediate results of treatment were estimated on the level of total PSA
change according to the international scale IPSS
Summary
Показаниями к проведению лечения пациентов с раком предстательной железы явились: стадия - Т1-2N0М0. Показаниями к лечению пациентов с почечно-клеточным раком: возраст ≥18 лет; гистологически верифицированная опухоль размерами до 5,0 см в диаметре; отказ от оперативного лечения. В исследование включено 77 пациентов с диагнозом рак предстательной железы, проанализированы 35 случаев. Диагноз: первично-множественный метахронный рак: 1) Рак левой почки рТ1вN0М0, после хирургического лечения – нефрэктомии слева в 2006г.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
